Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.

Print   Email View: All Filings Annual Quarterly Current Section 16 Proxy Other    Year: All Years 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 Filing Description Date Filed Size   4 seely, lynn May 16, 2012 25.8 KB 4 hung, david May 16, 2012 24.3 KB 4 machado, clarence patrick May 16, 2012 25.1 KB PRE 14A preliminary proxy statement May 16, 2012 773.7 KB 10-Q quarterly report May 9, 2012 646.9 KB 8-K current report May 8, 2012 77.8 KB 4 machado, clarence patrick May 1, 2012 25.8 KB 10-K/A amended annual report Apr 30, 2012 461.0 KB 8-K current report Mar 19, 2012 1.0 MB 424B2 prospectus filed pursuant to rule 424 Mar 15, 2012 917.3 KB FWP free writing prospectus - filing under securities act rules 163/433 Mar 14, 2012 40.6 KB 424B2 prospectus filed pursuant to rule 424 Mar 13, 2012 890.3 KB 4 seely, lynn Mar 12, 2012 28.7 KB 4 machado, clarence patrick Mar 12, 2012 25.1 KB S-3ASR automatic shelf registration statement of securities of well-known seasoned issuers Mar 12, 2012 1.1 MB 10-K annual report Feb 29, 2012 1.9 MB 8-K current report Feb 29, 2012 73.6 KB SC 13G/A amended statement of beneficial ownership Feb 14, 2012 61.9 KB SC 13G/A amended statement of beneficial ownership Feb 14, 2012 48.9 KB SC 13G/A amended statement of beneficial ownership Feb 13, 2012 60.9 KB Showing 1-20 of 613 Page: 1 2 3 ... 31  Next 20 = add filing to Briefcase